Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
GermanyIPO:
07 November 2017Website:
http://www.inflarx.deNext earnings report:
21 March 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 20 Nov 2024 14:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
IFRX Latest News
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.27.
JENA, Germany, Aug. 27, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in two investor conferences in September 2024. Details are as follows:
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21.
JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its second quarter 2024 financial and operating results on August 8, 2024, before the market opens. No conference call is planned.
JENA, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today hosted a virtual R&D event focused on the company's oral small molecule C5aR inhibitor, INF904. Speakers provided additional details on development rationales and plans for INF904, as well as additional insight into its potential role in CSU and HS and its broader therapeutic potential in the immuno-inflammation field.
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.20.
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company's anticipated development plans for INF904, InflaRx's orally available C5aR inhibitor with best-in-class potential. The Company will also publish its financial and operating results for the fourth quarter and full year 2023 on March 21, 2024, in advance of the call.
InflaRx N.V. (IFRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.
InflaRx N.V. (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
InflaRx N.V. (IFRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
What type of business is InflaRx NV?
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
What sector is InflaRx NV in?
InflaRx NV is in the Healthcare sector
What industry is InflaRx NV in?
InflaRx NV is in the Biotechnology industry
What country is InflaRx NV from?
InflaRx NV is headquartered in Germany
When did InflaRx NV go public?
InflaRx NV initial public offering (IPO) was on 07 November 2017
What is InflaRx NV website?
https://www.inflarx.de
Is InflaRx NV in the S&P 500?
No, InflaRx NV is not included in the S&P 500 index
Is InflaRx NV in the NASDAQ 100?
No, InflaRx NV is not included in the NASDAQ 100 index
Is InflaRx NV in the Dow Jones?
No, InflaRx NV is not included in the Dow Jones index
When was InflaRx NV the previous earnings report?
No data
When does InflaRx NV earnings report?
The next expected earnings date for InflaRx NV is 21 March 2025